NR605 Diagnosis & Management in Psychiatric-Mental
Health Across the Lifespan I Practicum - Final Exam Prep
Document | 2026/2027 Edition | 150 Verified Questions - 120
Questions with Answers
NR605 Final Exam 2026-120 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students enrolled
in NR605, focusing on diagnosis and management in psychiatric-mental health across the lifespan. It
contains 150 verified questions and answers, organized into three full exam sets, ensuring thorough
coverage of all critical concepts. Each question is accompanied by a detailed rationale and
evidence-based explanation, aligning with the latest DSM-5-TR and ANCC guidelines. This resource
is an essential tool for mastering the final exam and achieving a top grade.
Key Features:
Foundations of Psychiatric-Mental Health Nursing: Theoretical frameworks, therapeutic communication, and
ethical/legal principles.
Neurobiology and Psychopharmacology: Mechanisms of action, side effects, and nursing implications for
psychotropic medications.
Assessment and Diagnostic Reasoning: Comprehensive psychiatric assessment, mental status examination, and
differential diagnosis.
Mood Disorders: Major depressive disorder, bipolar disorders, and related conditions across the lifespan.
Anxiety and Trauma-Related Disorders: Generalized anxiety, panic, PTSD, OCD, and adjustment disorders.
Psychotic Disorders: Schizophrenia spectrum and other psychotic disorders, including management strategies.
Personality Disorders: Cluster A, B, and C personality disorders, with therapeutic approaches.
Substance Use and Addictive Disorders: Assessment, withdrawal management, and relapse prevention.
Neurodevelopmental and Cognitive Disorders: ADHD, autism spectrum, delirium, and dementia.
Child and Adolescent Psychiatry: Special considerations in diagnosis and treatment for pediatric populations.
Geriatric Psychiatry: Late-life mental health issues, polypharmacy, and age-specific interventions.
Crisis and Emergency Psychiatry: Suicide risk assessment, crisis intervention, and emergency management.
Integrated Care and Interprofessional Collaboration: Coordinating care with primary care and community
resources.
Evidence-Based Practice and Quality Improvement: Applying research findings to clinical decision-making.
Legal and Ethical Issues in Psychiatric Nursing: Informed consent, confidentiality, and mandatory reporting.
Cultural and Spiritual Considerations: Providing culturally competent care in psychiatric settings.
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and coding changes.
- Revised to incorporate 2026-2027 ANCC and AACN competency standards.
- Enhanced rationales with current evidence-based practice guidelines from APA and NICE.
- Expanded coverage of telehealth and digital health interventions in psychiatric care.
- Aligned with the latest safety and quality initiatives from The Joint Commission.
Abstract:
The NR605 final exam preparation document offers an exhaustive compilation of 150 verified questions and
answers, structured into three complete exam sets to mirror the actual test format. This resource is grounded in the
Page 1
,core competencies of psychiatric-mental health nursing, emphasizing diagnosis, management, and evidence-based
interventions across the lifespan. It integrates theoretical foundations with clinical application, addressing
neurobiological underpinnings, psychopharmacology, and therapeutic modalities. Special attention is given to
vulnerable populations, including children, adolescents, and older adults, as well as cultural and ethical
considerations. Each question is paired with a comprehensive rationale that explains the correct answer and
distractor analysis, facilitating deeper understanding and retention. The content is meticulously updated to align
with the 2026/2027 academic year, ensuring relevance and accuracy. This document serves as an indispensable
study aid for students aiming to excel in the final exam and future clinical practice.
Keywords:
NR605 final exam, Psychiatric-mental health nursing, DSM-5-TR, Lifespan psychiatry, Psychopharmacology,
Nurse practitioner exam prep, Verified questions and answers
Answer Format:
Each question is presented in a format consistent with the actual exam, followed by the correct answer and a
detailed rationale explaining why it is correct. Distractor explanations are also provided to clarify common
misconceptions and reinforce learning. All answers are verified by subject matter experts and aligned with current
evidence-based guidelines.
Compliance Checklist:
Aligned with the latest DSM-5-TR diagnostic criteria
Meets 2026-2027 ANCC certification exam blueprint
Incorporates AACN Essentials for advanced nursing practice
Includes evidence-based rationales from peer-reviewed sources
Covers all lifespan stages and diverse patient populations
Adheres to ethical and legal standards in psychiatric care
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations and Assessment 1-20 Theoretical frameworks, therapeutic 13%
communication, psychiatric assessment,
MSE
Neurobiology and 21-40 Neurotransmitters, psychotropic drug 13%
Psychopharmacology classes, side effects, monitoring
Mood and Anxiety Disorders 41-60 MDD, bipolar, GAD, panic, PTSD, OCD 13%
Psychotic and Personality 61-80 Schizophrenia, schizoaffective, personality 13%
Disorders clusters, management
Substance Use and Addictive 81-95 Alcohol, opioids, stimulants, withdrawal, 10%
Disorders relapse prevention
Child and Adolescent Psychiatry 96-110 ADHD, autism, conduct disorder, pediatric 10%
depression and anxiety
Geriatric Psychiatry 111-125 Delirium, dementia, late-life depression, 10%
polypharmacy
Crisis, Ethics, and Integrated 126-150 Suicide risk, crisis intervention, legal issues, 18%
Care collaborative care
Page 2
,Q1. In a patient with treatment-resistant schizophrenia who has failed two adequate
trials of non-clozapine antipsychotics, which combination of pharmacogenomic
findings would most strongly support the use of clozapine?
A. CYP1A2 poor metabolizer and HLA-DQB1 allele negative
B. CYP2D6 ultrarapid metabolizer and HLA-B*38 positive
C. CYP1A2 ultrarapid metabolizer and HLA-DQB1 negative
D. CYP2D6 poor metabolizer and HLA-B*57 positive
Correct Answer: C. CYP1A2 ultrarapid metabolizer and HLA-DQB1 negative
Rationale: Clozapine is primarily metabolized by CYP1A2; an ultrarapid metabolizer
would require higher doses, but the key pharmacogenomic factor is HLA-DQB1
(particularly HLA-DQB1*667) negativity, which reduces agranulocytosis risk. CYP2D6
status is less relevant, and HLA-B*57 is associated with abacavir hypersensitivity, not
clozapine.
Why Wrong:
A - CYP1A2 poor metabolizer would increase clozapine levels, not support use, and
HLA-DQB1 negative is correct but the CYP status is wrong.
B - HLA-B*38 is not a recognized clozapine risk marker; CYP2D6 ultrarapid is
irrelevant.
D - CYP2D6 poor metabolizer is not a primary consideration for clozapine, and
HLA-B*57 is unrelated to clozapine.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th ed., Ch. 5.
Q2. A patient with generalized anxiety disorder has been on sertraline 200 mg/day for
8 weeks with partial response. Which augmentation strategy is most likely to provide
additional benefit with the least risk of serotonin syndrome?
A. Adding buspirone 15 mg twice daily
B. Adding mirtazapine 30 mg at bedtime
C. Adding aripiprazole 2 mg daily
D. Adding gabapentin 300 mg three times daily
Correct Answer: A. Adding buspirone 15 mg twice daily
Rationale: Buspirone is a 5-HT1A partial agonist that augments SSRI response in GAD
without significantly increasing synaptic serotonin, thus low serotonin syndrome risk.
Mirtazapine has serotonergic mechanisms and can increase risk. Aripiprazole is not
FDA-approved for GAD and has metabolic risks. Gabapentin has limited evidence for
GAD augmentation.
Why Wrong:
B - Mirtazapine has serotonergic activity and may increase serotonin syndrome risk
when combined with an SSRI.
C - Aripiprazole is not a standard augmentation for GAD and carries metabolic side
Page 3
, effects.
D - Gabapentin has weak evidence for GAD augmentation and does not target the
underlying serotonergic deficit.
Reference: Bandelow, B., et al. (2023). World Journal of Biological Psychiatry, 24(5),
355-398.
Q3. According to the 2023 APA Practice Guideline for the Treatment of Patients with
Major Depressive Disorder, which of the following is the recommended first-line
treatment for a patient with severe MDD with psychotic features?
A. Antidepressant monotherapy with an SSRI
B. Antidepressant plus atypical antipsychotic combination
C. Electroconvulsive therapy (ECT)
D. Cognitive behavioral therapy (CBT) alone
Correct Answer: B. Antidepressant plus atypical antipsychotic combination
Rationale: The 2023 APA guideline recommends combination therapy with an
antidepressant and an antipsychotic (e.g., olanzapine-fluoxetine) as first-line for psychotic
depression, or ECT for severe cases. Antidepressant monotherapy is insufficient. CBT
alone is not appropriate for psychotic features.
Why Wrong:
A - Antidepressant monotherapy is not effective for psychotic depression and may
worsen psychosis.
C - ECT is a second-line option for treatment-resistant or severe cases, not first-line.
D - CBT alone is not recommended for psychotic depression.
Reference: APA (2023). Practice Guideline for the Treatment of Patients with Major
Depressive Disorder, 3rd ed.
Q4. A patient with bipolar I disorder is stabilized on lithium. Which of the following
concurrent medication combinations would most likely require a lithium dose
reduction?
A. Lithium + ACE inhibitor + thiazide diuretic
B. Lithium + calcium channel blocker (verapamil)
C. Lithium + loop diuretic (furosemide)
D. Lithium + NSAID (ibuprofen) + caffeine
Correct Answer: A. Lithium + ACE inhibitor + thiazide diuretic
Rationale: ACE inhibitors and thiazide diuretics both increase lithium reabsorption in the
proximal tubule, significantly raising serum lithium levels, often requiring dose reduction.
Loop diuretics have variable effects, NSAIDs increase lithium levels but caffeine may
counteract, and verapamil does not significantly affect lithium.
Page 4
Health Across the Lifespan I Practicum - Final Exam Prep
Document | 2026/2027 Edition | 150 Verified Questions - 120
Questions with Answers
NR605 Final Exam 2026-120 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students enrolled
in NR605, focusing on diagnosis and management in psychiatric-mental health across the lifespan. It
contains 150 verified questions and answers, organized into three full exam sets, ensuring thorough
coverage of all critical concepts. Each question is accompanied by a detailed rationale and
evidence-based explanation, aligning with the latest DSM-5-TR and ANCC guidelines. This resource
is an essential tool for mastering the final exam and achieving a top grade.
Key Features:
Foundations of Psychiatric-Mental Health Nursing: Theoretical frameworks, therapeutic communication, and
ethical/legal principles.
Neurobiology and Psychopharmacology: Mechanisms of action, side effects, and nursing implications for
psychotropic medications.
Assessment and Diagnostic Reasoning: Comprehensive psychiatric assessment, mental status examination, and
differential diagnosis.
Mood Disorders: Major depressive disorder, bipolar disorders, and related conditions across the lifespan.
Anxiety and Trauma-Related Disorders: Generalized anxiety, panic, PTSD, OCD, and adjustment disorders.
Psychotic Disorders: Schizophrenia spectrum and other psychotic disorders, including management strategies.
Personality Disorders: Cluster A, B, and C personality disorders, with therapeutic approaches.
Substance Use and Addictive Disorders: Assessment, withdrawal management, and relapse prevention.
Neurodevelopmental and Cognitive Disorders: ADHD, autism spectrum, delirium, and dementia.
Child and Adolescent Psychiatry: Special considerations in diagnosis and treatment for pediatric populations.
Geriatric Psychiatry: Late-life mental health issues, polypharmacy, and age-specific interventions.
Crisis and Emergency Psychiatry: Suicide risk assessment, crisis intervention, and emergency management.
Integrated Care and Interprofessional Collaboration: Coordinating care with primary care and community
resources.
Evidence-Based Practice and Quality Improvement: Applying research findings to clinical decision-making.
Legal and Ethical Issues in Psychiatric Nursing: Informed consent, confidentiality, and mandatory reporting.
Cultural and Spiritual Considerations: Providing culturally competent care in psychiatric settings.
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and coding changes.
- Revised to incorporate 2026-2027 ANCC and AACN competency standards.
- Enhanced rationales with current evidence-based practice guidelines from APA and NICE.
- Expanded coverage of telehealth and digital health interventions in psychiatric care.
- Aligned with the latest safety and quality initiatives from The Joint Commission.
Abstract:
The NR605 final exam preparation document offers an exhaustive compilation of 150 verified questions and
answers, structured into three complete exam sets to mirror the actual test format. This resource is grounded in the
Page 1
,core competencies of psychiatric-mental health nursing, emphasizing diagnosis, management, and evidence-based
interventions across the lifespan. It integrates theoretical foundations with clinical application, addressing
neurobiological underpinnings, psychopharmacology, and therapeutic modalities. Special attention is given to
vulnerable populations, including children, adolescents, and older adults, as well as cultural and ethical
considerations. Each question is paired with a comprehensive rationale that explains the correct answer and
distractor analysis, facilitating deeper understanding and retention. The content is meticulously updated to align
with the 2026/2027 academic year, ensuring relevance and accuracy. This document serves as an indispensable
study aid for students aiming to excel in the final exam and future clinical practice.
Keywords:
NR605 final exam, Psychiatric-mental health nursing, DSM-5-TR, Lifespan psychiatry, Psychopharmacology,
Nurse practitioner exam prep, Verified questions and answers
Answer Format:
Each question is presented in a format consistent with the actual exam, followed by the correct answer and a
detailed rationale explaining why it is correct. Distractor explanations are also provided to clarify common
misconceptions and reinforce learning. All answers are verified by subject matter experts and aligned with current
evidence-based guidelines.
Compliance Checklist:
Aligned with the latest DSM-5-TR diagnostic criteria
Meets 2026-2027 ANCC certification exam blueprint
Incorporates AACN Essentials for advanced nursing practice
Includes evidence-based rationales from peer-reviewed sources
Covers all lifespan stages and diverse patient populations
Adheres to ethical and legal standards in psychiatric care
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations and Assessment 1-20 Theoretical frameworks, therapeutic 13%
communication, psychiatric assessment,
MSE
Neurobiology and 21-40 Neurotransmitters, psychotropic drug 13%
Psychopharmacology classes, side effects, monitoring
Mood and Anxiety Disorders 41-60 MDD, bipolar, GAD, panic, PTSD, OCD 13%
Psychotic and Personality 61-80 Schizophrenia, schizoaffective, personality 13%
Disorders clusters, management
Substance Use and Addictive 81-95 Alcohol, opioids, stimulants, withdrawal, 10%
Disorders relapse prevention
Child and Adolescent Psychiatry 96-110 ADHD, autism, conduct disorder, pediatric 10%
depression and anxiety
Geriatric Psychiatry 111-125 Delirium, dementia, late-life depression, 10%
polypharmacy
Crisis, Ethics, and Integrated 126-150 Suicide risk, crisis intervention, legal issues, 18%
Care collaborative care
Page 2
,Q1. In a patient with treatment-resistant schizophrenia who has failed two adequate
trials of non-clozapine antipsychotics, which combination of pharmacogenomic
findings would most strongly support the use of clozapine?
A. CYP1A2 poor metabolizer and HLA-DQB1 allele negative
B. CYP2D6 ultrarapid metabolizer and HLA-B*38 positive
C. CYP1A2 ultrarapid metabolizer and HLA-DQB1 negative
D. CYP2D6 poor metabolizer and HLA-B*57 positive
Correct Answer: C. CYP1A2 ultrarapid metabolizer and HLA-DQB1 negative
Rationale: Clozapine is primarily metabolized by CYP1A2; an ultrarapid metabolizer
would require higher doses, but the key pharmacogenomic factor is HLA-DQB1
(particularly HLA-DQB1*667) negativity, which reduces agranulocytosis risk. CYP2D6
status is less relevant, and HLA-B*57 is associated with abacavir hypersensitivity, not
clozapine.
Why Wrong:
A - CYP1A2 poor metabolizer would increase clozapine levels, not support use, and
HLA-DQB1 negative is correct but the CYP status is wrong.
B - HLA-B*38 is not a recognized clozapine risk marker; CYP2D6 ultrarapid is
irrelevant.
D - CYP2D6 poor metabolizer is not a primary consideration for clozapine, and
HLA-B*57 is unrelated to clozapine.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th ed., Ch. 5.
Q2. A patient with generalized anxiety disorder has been on sertraline 200 mg/day for
8 weeks with partial response. Which augmentation strategy is most likely to provide
additional benefit with the least risk of serotonin syndrome?
A. Adding buspirone 15 mg twice daily
B. Adding mirtazapine 30 mg at bedtime
C. Adding aripiprazole 2 mg daily
D. Adding gabapentin 300 mg three times daily
Correct Answer: A. Adding buspirone 15 mg twice daily
Rationale: Buspirone is a 5-HT1A partial agonist that augments SSRI response in GAD
without significantly increasing synaptic serotonin, thus low serotonin syndrome risk.
Mirtazapine has serotonergic mechanisms and can increase risk. Aripiprazole is not
FDA-approved for GAD and has metabolic risks. Gabapentin has limited evidence for
GAD augmentation.
Why Wrong:
B - Mirtazapine has serotonergic activity and may increase serotonin syndrome risk
when combined with an SSRI.
C - Aripiprazole is not a standard augmentation for GAD and carries metabolic side
Page 3
, effects.
D - Gabapentin has weak evidence for GAD augmentation and does not target the
underlying serotonergic deficit.
Reference: Bandelow, B., et al. (2023). World Journal of Biological Psychiatry, 24(5),
355-398.
Q3. According to the 2023 APA Practice Guideline for the Treatment of Patients with
Major Depressive Disorder, which of the following is the recommended first-line
treatment for a patient with severe MDD with psychotic features?
A. Antidepressant monotherapy with an SSRI
B. Antidepressant plus atypical antipsychotic combination
C. Electroconvulsive therapy (ECT)
D. Cognitive behavioral therapy (CBT) alone
Correct Answer: B. Antidepressant plus atypical antipsychotic combination
Rationale: The 2023 APA guideline recommends combination therapy with an
antidepressant and an antipsychotic (e.g., olanzapine-fluoxetine) as first-line for psychotic
depression, or ECT for severe cases. Antidepressant monotherapy is insufficient. CBT
alone is not appropriate for psychotic features.
Why Wrong:
A - Antidepressant monotherapy is not effective for psychotic depression and may
worsen psychosis.
C - ECT is a second-line option for treatment-resistant or severe cases, not first-line.
D - CBT alone is not recommended for psychotic depression.
Reference: APA (2023). Practice Guideline for the Treatment of Patients with Major
Depressive Disorder, 3rd ed.
Q4. A patient with bipolar I disorder is stabilized on lithium. Which of the following
concurrent medication combinations would most likely require a lithium dose
reduction?
A. Lithium + ACE inhibitor + thiazide diuretic
B. Lithium + calcium channel blocker (verapamil)
C. Lithium + loop diuretic (furosemide)
D. Lithium + NSAID (ibuprofen) + caffeine
Correct Answer: A. Lithium + ACE inhibitor + thiazide diuretic
Rationale: ACE inhibitors and thiazide diuretics both increase lithium reabsorption in the
proximal tubule, significantly raising serum lithium levels, often requiring dose reduction.
Loop diuretics have variable effects, NSAIDs increase lithium levels but caffeine may
counteract, and verapamil does not significantly affect lithium.
Page 4
